Astellas Pharma

ONE WEEK LEFT to enter the Astellas Future Innovator Prize 2025. Don’t miss this chance to accelerate your biotech innovation with MBC BioLabs and Astellas. The winner will receive one year of lab bench and research instrument access at MBC BioLabs, along with mentorship from Astellas’ R&D scientists, business leaders, and experts.   Time is running out—apply now.  https://lnkd.in/gCC29_-X     #incubator #BiotechStartup #entrepreneurs  

We would like to take a moment to recognize Yoshitsugu Shitaka, Hideki Shima and Catherine Levitt on their upcoming retirements from Astellas. Each of these leaders made invaluable contributions during their distinguished and impactful careers. We are deeply grateful and they will be profoundly missed.    #retirement #leadership 

In research, it is not always possible to design head-to-head trials, comparing different treatments directly. However, we can evaluate treatment outcome profiles of different therapies using matching-adjusted indirect comparison (MAIC) analyses. Professor Andrew Armstrong offers his views on their benefits – as well as limitations - and how their findings can contribute to our understanding of treatment outcomes.  #MAICanalysis #ScienceFirstForPatients 

Behind our leading cell and gene therapy programs is an ambitious, long-term strategy to transform patient lives.     Richard Wilson, Primary Focus Lead, Genetic Regulation, and Yoshitsugu Shitaka, Chief Scientific Officer, shared more about our approach with Cell & Gene.      From bringing experts together at our new West Coast Innovation Center, to leveraging expertise across therapeutic modalities and using cutting-edge AI and automated processes to accelerate progress – read on to learn more:  https://lnkd.in/gzM5Mq23    #ChangingTomorrow #CellAndGeneTherapies 

Although direct comparisons are always preferred, it is not always possible or affordable to conduct them. Experts can utilize other methods, including a matching-adjusted indirect comparison (MAIC). With this method, research can be conducted to understand and compare treatment outcomes – even when the clinical studies in question have population differences. Professor Andrew Armstrong, Director of Research at Duke Cancer Institute, explores what MAIC analyses entail, including their benefits and limitations, and how variations in patient characteristics can be adjusted, to give a comparative data picture.   #MAICanalysis #ScienceFirstForPatients 

At Astellas, #sustainability is an imperative, not an option. Our commitment to achieving net-zero emissions by 2050 shapes every decision we make. In our latest article, we highlight the Astellas Sustainable Business Partner Summit, where we brought together suppliers representing 80% of the company’s overall spending to emphasize the importance of #collaboration in tackling scope 3 emissions, which account for 90% of our carbon footprint. From innovative packaging to logistics improvements, we are committed to aligning our operations with our environmental goals. We invite our partners to join us in building a sustainable future for generations to come. Read more about our journey on our corporate website: https://bit.ly/3FvHn4m #NetZero

Digital transformation plays a key role in many areas of the drug development process, especially in manufacturing and supply. Hideki Shima, our Chief Manufacturing Officer, recently shared how we are transforming our approach to data utilization and knowledge management efforts by implementing a comprehensive digital transformation roadmap.   A standout feature of our initiatives is our proprietary data mining platform, DAIMON (Data Analysis and Integration for Multivariate mONitoring). This innovative tool enables us to automatically pool the vast data sets and conduct real-time analysis, allowing us to easily identify potential risks and investigate the causes of any issues that arise in the real world.       By harnessing the power of digital technologies, we are continuously enhancing our manufacturing process development and boosting productivity to ensure a stable supply of quality products for patients. Together, we are shaping the future of our industry through data-driven insights and digital transformation.   https://lnkd.in/gzncuCDu   #DigitalTransformation #manufacturing #InterphexWeek

Vision impairment from degenerative eye diseases affects millions of people worldwide and can have a devastating impact on quality of life. At Astellas, we are dedicated to developing transformative therapies to restore sight and free patients from the fear of deteriorating vision. Our research targets conditions like age-related macular degeneration, glaucoma, and retinitis pigmentosa, which stem from the gradual loss of retinal cells. And we are working at the cutting-edge of cell therapy and gene therapy to deliver innovative therapies in ophthalmology. Pioneering new treatments utilizing new modalities cannot be achieved in isolation. Working collaboratively with experts from fields including ophthalmology and regenerative medicine, we have greater potential to succeed. Together, we can work toward restoring vision and enhancing the quality of life for those affected by degenerative eye diseases. Read more about our initiatives in ophthalmology in this Nature Outlook Vision sponsored article here: https://lnkd.in/gXafAHVv #ChangingTomorrow #ophthamology #CellTherapy #GeneTherapy

Ahead of #InternationalWomensDay tomorrow, Astellas is proud to launch findings from The Menopause Experience & Attitudes Study (MEAS), a research initiative developed in partnership with external experts, to examine and track societal attitudes, personal experiences, and the stigma surrounding menopause and perimenopause across the U.S., Canada, Germany, Australia, Brazil, and Mexico. The study highlights the urgent need to shift societal perceptions of menopause, given that only 25% of women believe it's portrayed positively. Read more here: https://bit.ly/3DoxEfE #menopause #WomensHealth #MenopauseExperience

We are excited to announce that Astellas has signed a definitive agreement with YASKAWA Electric Corporation to establish a joint venture to develop and provide a cell therapy product manufacturing platform utilizing the humanoid robot "Maholo."    Through establishing the joint venture, Astellas is committed to developing an automation platform for cell therapy products and providing it to academia and startup companies in implementing innovative cell therapies for patients with limited or no treatment options.    Read more: https://lnkd.in/gkPTTr_x #CellTherapy #robotics #manufacturing